SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-C

CURRENT REPORT UNDER SECTION 17
OF THE SECURITIES REGULATION CODE
AND SRC RULE 17.2(c) THEREUNDER

1. Date of Report (Date of earliest event reported)

Mar 20, 2017

2. SEC Identification Number

A200016575

3. BIR Tax Identification No.

055-695-791

4. Exact name of issuer as specified in its charter

PHILAB HOLDINGS CORP. (formerly Alterra Capital Partners, Inc.)

5. Province, country or other jurisdiction of incorporation

Philippines

6. Industry Classification Code(SEC Use Only)

7. Address of principal office

8th Floor, 1128 38th Avenue, Fort Bonifacio Global City, Taguig City, Metro Manila Postal Code 1634

8. Issuer's telephone number, including area code

(02)5519639

9. Former name or former address, if changed since last report

N/A

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
Common Shares	62,276,060

11. Indicate the item numbers reported herein

Item 9

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Philab Holdings Corp.DNA

PSE Disclosure Form 4-2 - Acquisition/Disposition of Shares of Another Corporation
References: SRC Rule 17 (SEC Form 17-C) and
Section 4.4 of the Revised Disclosure Rules

Subject of the Disclosure
Acquisition of the Company of 100% of the shareholdings of MedX Pte. Ltd. (“MedX”).
Background/Description of the Disclosure
This is in compliance with the request for additional information by the PSE regarding the Company’s disclosure dated 17 March 2017 pertaining to the Company’s acquisition of 200 shares or 100% of MedX for Two Singapore Dollars (S$2.00)

Date of Approval by Board of Directors	Mar 17, 2017

Rationale for the transaction including the benefits which are expected to be accrued to the Issuer as a result of the transaction
The Company is contemplating the launching of Project MeDx, although no definitive steps or action have yet been taken. MedX is envisioned to be a transformative complete healthcare platform aimed at providing greater accessibility to healthcare.

Details of the acquisition or disposition

Date	Mar 17, 2017

Manner
The Company paid for the acquisition of 200 shares or 100% of the shareholdings of MedX in cash.
Description of the company to be acquired or sold
MedX currently has no operations, but the Company may use MedX to house a line of business in the future. Please see above for the description of MedX.

The terms and conditions of the transaction

Number of shares to be acquired or disposed	200
Percentage to the total outstanding shares of the company subject of the transaction	100
Price per share	0.01 Singapore Dollars

Nature and amount of consideration given or received
Full payment in cash of Two Singapore Dollars (S$2.00)
Principle followed in determining the amount of consideration
Lowest acceptable consideration according to Singapore Law given that the company is a shell company and is not operating.
Terms of payment
Full payment in cash
Conditions precedent to closing of the transaction, if any
None.
Any other salient terms
None.

Identity of the person(s) from whom the shares were acquired or to whom they were sold

Name	Nature of any material relationship with the Issuer, their directors/ officers, or any of their affiliates
Chan Wai Leong	Chan Wai Leong (Transferor) is currently a director of the Company.
Hector Thomas A. Navasero	Hector Thomas A. Navasero (Transferor) is currently the Executive Chairman of the Company.

Effect(s) on the business, financial condition and operations of the Issuer, if any
The Company may use MedX to house a line of business in the future. The effect on the business, financial condition and operations of the Company cannot be determined as of this time.
Other Relevant Information
None.